Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the safety, tolerability, how the body processes, and the effectiveness of HRS-6209 in adults with hormone receptor-positive and HER2-negative solid tumors, including breast cancer. This Phase 1 trial aims to understand these aspects in patients with this type of cancer. The study is sponsored by Atridia Pty Ltd. and focuses on evaluating this combination treatment to provide more information for future care options. Participants will receive HRS-6209 capsules at a dose of 100 mg twice daily for four weeks along with a single dose of fulvestrant injection. This combination therapy is given as the experimental treatment. The trial follows a single group design without a comparison group, focusing on this combinations effects and safety during the treatment period. During the study, participants will be monitored for adverse events and serious side effects from screening through about one year after enrollment. Researchers will also measure the drug concentrations in the body up to four months and evaluate tumor response and disease control for up to two years. Participants can expect regular visits and assessments to track safety, response to treatment, and disease progression throughout the study period.
Actively Recruiting
Researchers are studying BGB-43395, a selective CDK4 inhibitor, to evaluate its safety, dosing, and antitumor activity in participants with hormone receptor positive HR and HER2-negative breast cancer as well as other advanced solid tumors. The study includes both monotherapy and combination treatments with fulvestrant, letrozole, or elacestrant. The main goal is to determine the recommended dosing for BGB-43395 in these conditions. The trial has two main phases Phase 1a focuses on dose escalation with sequential groups receiving increasing doses of BGB-43395 alone or combined with fulvestrant, letrozole, or elacestrant. Phase 1b involves dose expansion cohorts where participants receive the recommended dose identified in Phase 1a, combined with either fulvestrant or letrozole, including preventive anti-diarrheal treatment in one cohort. Treatments are given orally or by injection depending on the drug. Participants undergo regular safety evaluations, blood tests to measure drug levels, and tumor assessments to monitor response over up to approximately 60 months. Researchers track adverse events, determine maximum tolerated doses, and assess objective response rates and other clinical outcomes. The study is non-randomized and open-label, led by BeOne Medicines, with ongoing monitoring during and after treatment to assess safety and effectiveness.